Durable Remissions in CLL With Fixed-Duration Triplet at 4 Years

(MedPage Today) -- Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL) were presented at the American Society of...